Pefloxacin was administered to 24 geriatric patients as treatment for lower respiratory tract infections contracted in hospital. Efficacy was evaluated by clinical, bacteriological and radiological parameters. Two-thirds of the patients responded well to therapy. Only two of 30 pathogens were not eradicated, but seven patients had superinfection or colonization by another organism. Tolerance was excellent, with only slight gastro-intestinal disorders. Pefloxacin was shown to be an effective and safe therapy for lower respiratory tract infections contracted in hospital in elderly patients.
Get full access to this article
View all access options for this article.
References
1.
KingAPhillipsI: The comparative in vitro activity of pefloxacin. J Antimicrob Chemother1986; 17 (suppl B); 1–10
2.
YourassowskyEVan der LindenMPCrokaertF: In-vitro activity of pefloxacin compared to other antibiotics. J Antimicrob Chemother1986: 17 (suppl B); 19–28
3.
AuckenthalerRMichea-HamzehpourMPechereJC: In-vitro activity of newer quinolones against aerobic bacteria. J Antimicrob Chemother1986; 17 (suppl B); 29–39
4.
RolinOHuetYBouanchaudDH: Comparative efficacy of pefloxacin and six other antimicrobial agents on Staphylococcus aureus experimental abscesses. J Antimicrob Chemother1986; 17 (suppl B); 49–52
5.
FrydmanAMLe RouxYLefebvreMA: Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers. J Antimicrob Chemother1986; 17 (suppl B); 65–79
6.
MontayGGoueffonYRoquetF: Absorption, distribution, metabolic fate and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys and humans. Antimicrob Agents Chemother1984; 25: 463–472.
7.
PangonBGehannoPDaldossC: Tissue diffusion of pefloxacin: (study in man). In: Proceedings of the 13th International Congress on Chemotherapy, Vienna (SpitzyKHKarrerK, eds). PS 4.6/4, part 110, 1983; pp 29–31.
8.
MontayGJacquotCBarietyJ: Pharmacokinetics of pefloxacin in renal insufficiency. Eur J Clin Pharmacol1985; 29: 345–349.
9.
DanauGMontayGCunciR: Pefloxacin kinetics in cirrhosis. Clin Pharmacol Ther1985; 38: 439–442.
10.
MorelCVergnaudMLangeardM: Pefloxacine: diffusion dans le mucus bronchique. Pathol Biol (Paris) 1984; 32: 516–519.
11.
LauwersSVinckenWNaessensA: Efficacy and safety of pefloxacin in the treatment of severe infections in patients hospitalized in intensive care units. J Antimicrob Chemother1986; 17 (suppl B); 111–115
12.
MaesenFPVDaviesBITeengsJP: Pefloxacin in acute exacerbations of chronic bronchitis. J Antimicrob Chemother1985; 16: 379–388.
13.
FourrierFChopinC: Comparative randomised trial of pefloxacin vs. usual antibiotherapy for severe bronchopneumonia in I.C.V. patients. In: Abstract book of the 25th International Conference on Antimicrobial Agents and Chemotherapy, Minneapolis, abstract 874, 1985; p 253.
14.
VanderdoncktJ: Pefloxacin in lower respiratory tract infections acquired in a long stay hospital. Proceedings of the International Symposium on New Quinolones, Geneva, July, 1986. Rev Infect Dis (in press).
15.
BauerAWKirbyWMMSherrisJC: Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol1966; 45: 493.
16.
BenardYLemenagerJMorelC: Biochemical evaluation of pefloxacin in infectious bronchopulmonary disease. In: Proceedings of the 13th International Congress on Chemotherapy, Vienna (SpitzyKHKarrerK, eds). PS 4.6/4, part 110, 1983; pp 39–44.
